CN111247123A - 肽共轭物、共轭过程及其用途 - Google Patents
肽共轭物、共轭过程及其用途 Download PDFInfo
- Publication number
- CN111247123A CN111247123A CN201880055703.0A CN201880055703A CN111247123A CN 111247123 A CN111247123 A CN 111247123A CN 201880055703 A CN201880055703 A CN 201880055703A CN 111247123 A CN111247123 A CN 111247123A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- compound
- peptide
- formula
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ73500817 | 2017-08-30 | ||
| NZ735008 | 2017-08-30 | ||
| PCT/IB2018/056611 WO2019043604A1 (en) | 2017-08-30 | 2018-08-30 | PEPTIDE CONJUGATES, CONJUGATION METHOD, AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111247123A true CN111247123A (zh) | 2020-06-05 |
Family
ID=65526296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880055703.0A Pending CN111247123A (zh) | 2017-08-30 | 2018-08-30 | 肽共轭物、共轭过程及其用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200361864A1 (https=) |
| EP (1) | EP3676250A4 (https=) |
| JP (1) | JP2020532534A (https=) |
| KR (1) | KR20200058424A (https=) |
| CN (1) | CN111247123A (https=) |
| AU (1) | AU2018323043A1 (https=) |
| BR (1) | BR112020003907A2 (https=) |
| CA (1) | CA3073314A1 (https=) |
| EA (1) | EA202090319A1 (https=) |
| IL (1) | IL272931A (https=) |
| MX (1) | MX2020002084A (https=) |
| SG (1) | SG11202001602QA (https=) |
| TW (1) | TW201925240A (https=) |
| WO (1) | WO2019043604A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2618842B1 (en) | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| AU2018391325B2 (en) | 2017-12-21 | 2024-07-11 | Axelia Oncology Pty Ltd | Optimised compounds |
| MX2021015961A (es) * | 2019-06-26 | 2022-03-22 | Ena Respiratory Pty Ltd | Moleculas novedosas. |
| CN110681362B (zh) * | 2019-09-26 | 2020-09-11 | 浙江大学 | 以羧基和吲哚基为功能基团的混合模式层析介质 |
| CN111349054A (zh) * | 2020-01-21 | 2020-06-30 | 青岛科技大学 | 一种防锈剂2-(1,3-苯并噻唑-2-硫基)丁二酸的制备方法 |
| JP7744936B2 (ja) * | 2020-06-26 | 2025-09-26 | イーナ レスパラトリー ピーティーワイ リミテッド | 分岐脂質化合物 |
| WO2023028661A1 (en) * | 2021-09-02 | 2023-03-09 | Ena Respiratory Pty Ltd | Formulation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028246A2 (en) * | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
| CN105555756A (zh) * | 2013-06-28 | 2016-05-04 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| CN108884020A (zh) * | 2016-02-26 | 2018-11-23 | 奥克兰联合服务有限公司 | 氨基酸及肽共轭物以及共轭过程 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4615805B2 (ja) * | 1999-11-15 | 2011-01-19 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ny−eso−1ペプチド誘導体およびその使用 |
| JP2012523379A (ja) * | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
-
2018
- 2018-08-30 EP EP18850403.9A patent/EP3676250A4/en not_active Withdrawn
- 2018-08-30 MX MX2020002084A patent/MX2020002084A/es unknown
- 2018-08-30 WO PCT/IB2018/056611 patent/WO2019043604A1/en not_active Ceased
- 2018-08-30 SG SG11202001602QA patent/SG11202001602QA/en unknown
- 2018-08-30 BR BR112020003907-1A patent/BR112020003907A2/pt not_active Application Discontinuation
- 2018-08-30 US US16/638,185 patent/US20200361864A1/en not_active Abandoned
- 2018-08-30 CA CA3073314A patent/CA3073314A1/en active Pending
- 2018-08-30 TW TW107130372A patent/TW201925240A/zh unknown
- 2018-08-30 JP JP2020512441A patent/JP2020532534A/ja active Pending
- 2018-08-30 AU AU2018323043A patent/AU2018323043A1/en not_active Abandoned
- 2018-08-30 CN CN201880055703.0A patent/CN111247123A/zh active Pending
- 2018-08-30 EA EA202090319A patent/EA202090319A1/ru unknown
- 2018-08-30 KR KR1020207009057A patent/KR20200058424A/ko not_active Withdrawn
-
2020
- 2020-02-26 IL IL272931A patent/IL272931A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028246A2 (en) * | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
| CN105555756A (zh) * | 2013-06-28 | 2016-05-04 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| CN108884020A (zh) * | 2016-02-26 | 2018-11-23 | 奥克兰联合服务有限公司 | 氨基酸及肽共轭物以及共轭过程 |
Non-Patent Citations (1)
| Title |
|---|
| GEETANJALI AGNIHOTRI等: "Structure✓Activity Relationships in Toll-Like Receptor 2-Agonists Leading to Simplified Monoacyl Lipopeptides", 《J.MED.CHEM.》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3676250A1 (en) | 2020-07-08 |
| IL272931A (en) | 2020-04-30 |
| CA3073314A1 (en) | 2019-03-07 |
| KR20200058424A (ko) | 2020-05-27 |
| MX2020002084A (es) | 2020-03-24 |
| JP2020532534A (ja) | 2020-11-12 |
| EP3676250A4 (en) | 2021-05-26 |
| SG11202001602QA (en) | 2020-03-30 |
| TW201925240A (zh) | 2019-07-01 |
| US20200361864A1 (en) | 2020-11-19 |
| AU2018323043A1 (en) | 2020-03-05 |
| WO2019043604A1 (en) | 2019-03-07 |
| EA202090319A1 (ru) | 2020-10-16 |
| BR112020003907A2 (pt) | 2020-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019200884B2 (en) | Amino acid and peptide conjugates and conjugation process | |
| CN111247123A (zh) | 肽共轭物、共轭过程及其用途 | |
| JP7161404B2 (ja) | アミノ酸及びペプチド接合体及び接合方法 | |
| KR20170094449A (ko) | 아미노산 및 펩타이드 접합체 및 이들의 용도 | |
| HK40013754A (en) | Peptides for amino acid and peptide conjugates and conjugation process | |
| HK1224279B (en) | Amino acid and peptide conjugates and conjugation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |